Nuvo Pharmaceuticals (OTCMKTS:MRVFF) & Vaxxinity (NASDAQ:VAXX) Critical Analysis

Risk and Volatility

Vaxxinity has a beta of 3.35, meaning that its share price is 235% more volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Vaxxinity and Nuvo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%

Earnings and Valuation

This table compares Vaxxinity and Nuvo Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93 million	($0.45)	0.00
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16

Nuvo Pharmaceuticals has higher revenue and earnings than Vaxxinity. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 7.0% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.